lysophosphatidic acid has been researched along with African Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barz, D; Berod, L; Idzko, M; Kamradt, T; Lagadari, M; Lehmann, K; Maghazachi, AA; Norgauer, J; Truta-Feles, K; Ziemer, M | 1 |
| Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J | 1 |
2 other study(ies) available for lysophosphatidic acid and African Lymphoma
| Article | Year |
|---|---|
Lysophosphatidic acid inhibits the cytotoxic activity of NK cells: involvement of Gs protein-mediated signaling.
Topics: Burkitt Lymphoma; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Cyclic AMP-Dependent Protein Kinases; Cytotoxicity, Immunologic; Down-Regulation; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gs; Humans; Immunologic Surveillance; Killer Cells, Natural; Lysophospholipids; Melanoma; p38 Mitogen-Activated Protein Kinases; Perforin; Phosphatidylinositol 3-Kinases; Receptors, Lysophosphatidic Acid; Signal Transduction; Tumor Escape | 2009 |
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine | 2008 |